• Quinolone–Coumarin Hybrids Against Toxoplasma gondii

  2026-08-31

  This 2024 Acta Parasitologica study evaluated 12 quinolone–coumarin hybrids derived from fluoroquinolone and novobiocin scaffolds against intracellular Toxoplasma gondii. QC1, QC3, QC6, and novobiocin showed the most favorable balance of antiparasitic activity and host-cell tolerance, supporting scaffold hybridization as a source of new anti-Toxoplasma leads while highlighting the limits of translating antibacterial activity directly into antiparasitic efficacy.

• 2',7'-Dichlorofluorescein diacetate: ROS Guide

  2026-08-30

  Build a practical intracellular ROS measurement workflow with 2',7'-Dichlorofluorescein diacetate across microscopy, flow cytometry, and plate assays. The guide also explains how to use this broad redox readout to interrogate ROS-responsive nanocarriers without overstating what the fluorescence signal proves.

• EdU Flow Cytometry Assay Kits (Cy5) Guide

  2026-08-29

  EdU Flow Cytometry Assay Kits (Cy5) provide an endpoint method for quantifying DNA synthesis during S phase by labeling incorporated EdU with a Cy5 azide through copper-catalyzed click chemistry. The assay is suited to fixed-cell flow cytometry, cell-cycle analysis, and treatment-response studies, but not to live-cell imaging or workflows that cannot tolerate copper-catalyzed chemistry.

• H 89 2HCl: From PKA Mechanism to Translation

  2026-08-28

  A mechanistic and strategic guide to using H 89 2HCl for interrogating cAMP/PKA signaling, neuronal calcium dynamics, protein phosphorylation, and translational assay design.

• From DEVD Signal to Translational Apoptosis Insight

  2026-08-28

  A mechanistic and strategic guide to using DEVD-dependent caspase-3 activity as a functional bridge between cell-death biology, assay validation, and translational decision-making.

• Ibrexafungerp: From MICs to In Vivo Evidence

  2026-08-27

  Ibrexafungerp, also known as MK 3118, links a distinct glucan-synthase mechanism with oral exposure and activity against resistant Candida. This article explains how susceptibility assays and delayed-treatment animal models improve translational interpretation.

• PEP, cGAS–STING, and Healthy Aging

  2026-08-27

  The reference study identifies phosphoenolpyruvate (PEP) as an age-responsive glycolytic metabolite that restrains cGAS–STING-driven inflammation. Its longitudinal, mechanistic, and disease-model evidence connects metabolic state with inflammaging while also showing why PEP findings should not be directly equated with evidence for hexose diphosphate.

• SNS-032: Reading CDK9 and RNA Pol II Signals

  2026-08-26

  SNS-032 (BMS-387032) is a selective CDK2, CDK7, and CDK9 inhibitor whose RNA Pol II phosphorylation profile can connect kinase engagement with transcriptional and cancer phenotypes. This article develops an assay-centered framework and carefully distinguishes SNS-032 evidence from related CDK9 findings in SARS-CoV-2 research.

• EDTA-Free Protease Inhibitor for OXPHOS Assays

  2026-08-26

  Discover how a Protease Inhibitor Cocktail supports reliable OXPHOS cancer assays by preserving protein integrity during extraction. This guide connects EDTA-free protease control with LRPPRC–dasatinib mechanism validation and practical assay design.

• YTHDF1 Phase Separation in SSC Fate Transition

  2026-08-25

  Fang et al. show that liquid-liquid phase separation by the m6A reader YTHDF1 promotes direct conversion of spermatogonial stem cells into neural stem cell-like cells. The work connects YTHDF1 condensates to selective suppression of IκBα/β mRNA translation and activation of the IκB–NF-κB–CCND1 axis, providing a mechanistic framework for studying RNA-mediated cell-fate transitions.

• Metabolic Intervention for Ferroptosis and Cuproptosis

  2026-08-25

  The 2024 Chemical Engineering Journal study develops a copper-based liposome nanosystem that combines glycolysis and NAD+ metabolic intervention with copper delivery to sensitize tumors to ferroptosis and cuproptosis. By weakening antioxidant capacity, ATP-dependent copper export, and tumor metabolic support, the strategy also promotes immunogenic cell death and antitumor immune activity.

• α-Linolenic Acid: Applied Research Workflows

  2026-08-24

  Build reproducible ALA experiments around lipid flux, cardiovascular phenotypes, inflammation, and carefully bounded immune assays. This guide combines practical dosing, storage, controls, and troubleshooting with a clear distinction between evidence for α-Linolenic Acid and findings reported for arachidonic acid.

• Camostat Mesilate: From Protease Tool to Assay Logic

  2026-08-24

  Camostat Mesilate is a trypsin-like protease inhibitor whose value spans ENaC biology, plasmin–TGF-β signaling, and fibrosis research. This article develops an assay-selection framework that distinguishes protease modulation from structure-guided protein–protein interaction inhibition.

• How Kinase Inhibitors Tune p38α Dephosphorylation

  2026-08-23

  The reference preprint identifies a dual-action mode in which selected p38α MAP kinase inhibitors both suppress kinase activity and accelerate WIP1-mediated dephosphorylation of the activation loop. Biochemical assays and X-ray structures link this effect to an inhibitor-stabilized activation-loop conformation that exposes the phospho-threonine, suggesting a route toward greater kinase-inhibitor specificity beyond active-site binding alone.

• PCR Fidelity in Neurodegeneration Research

  2026-08-22

  Translational neuroscience increasingly depends on molecular measurements that remain trustworthy across complex templates, environmental exposures, and high-throughput workflows. This article examines how mechanistic findings in C. elegans neurodegeneration create a practical need for accurate amplification and explains where HyperFusion™ high-fidelity DNA polymerase can strengthen cloning, genotyping, and sequencing strategies without overstating what PCR alone can prove.

8237 records 1/550 page Next 12345 下5页 Last page